Daily aspirin may slash liver cancer risk in cirrhosis patients
NCT ID NCT07529262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check-ups. If successful, aspirin could become a simple, low-cost way to protect against liver cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 890 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provide written informed consent to participate in the trial according to ICH GCP (R3) and national/local regulations. * Diagnosed with liver cirrhosis for at least 6 months * Has a current Child-Pugh score ≤6 (Child A - clinically and biochemically compensated cirrhosis) * Has been participating in ultrasound or non-ultrasound (computed tomography (CT) or magnetic resonance imaging (MRI)) based surveillance for at least 6 months prior to entry. * Has not had any focal lesions, other than haemangiomas, detected during the past 6 months. Exclusion Criteria: * Any of the following: * autoimmune liver disease. * primary biliary cholangitis. * primary sclerosing cholangitis. * prior HCC * alcohol consumption \>3 standard drinks per day in men and 2 standard drinks per day in women. * currently taking a nonsteroidal anti-inflammatory drug, anticoagulant drugs, non-vitamin K anticoagulant frugs, or other antiplatelet drugs, including aspirin, within the last 6 months. * a known bleeding disorder * a platelet count \<50 x 109/L. * known history or endoscopic evidence of high risk oesophageal (grade 2 or higher) or gastric varices or, a history of bleeding varices. * chronic iron deficiency anaemia. * a prior history of liver decompensation or liver transplantation. * known peptic ulcer disease. * chronic kidney disease with eGFR \<50ml/min; a contraindication to aspirin. * Any participant considered by the PI to be deemed unlikely to complete the study due to other comorbid conditions or poor compliance will also be excluded. Pregnancy: * Whilst low dose aspirin is considered safe in pregnancy, male and female participants of child-bearing potential are recommended use effective contraception during this trial. * Any female participants who fall pregnant during the trial will be withdrawn if their treating obstetric doctor advises that you should do so.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Liver cirrhosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria in a capsule: a new attempt to calm a brain complication of cirrhosis
- Can a digital platform catch liver cancer sooner?
- Can a Two-Drug combo keep cirrhosis patients out of the hospital?
- Can removing the spleen help the liver fight cancer?
- Blood test may forecast which cirrhosis patients survive after discharge
- Can a parasite drug help fight a deadly gut infection in cirrhosis?